Bayer vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Merck & is more profitable, grows faster, is cheaper for its profits and has less debt.
Side by side
| Bayer | Merck & | |
|---|---|---|
| €55.5 billion | $364 billion | |
| -7.9% | 28.1% | |
| −3.5% | +9.4% | |
| No profit yet | 20.0× | |
| 15.5 years | 1.2 years | |
| -1.0% | 17.8% | |
| 0.2% | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Bayer vs Roche · Bayer vs Johnson & Johnson · Bayer vs Eli Lilly · Merck & vs Gilead Sciences · Merck & vs Intuitive Surgical · Merck & vs Johnson & Johnson · Merck & vs Eli Lilly